(Q37987212)

26 August 2017

title

Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia (English)

1 reference

26 August 2017

0 references

1 reference

1 reference

ChEBI release 2020-05-28

Sean T Duggan

1

1 reference

26 August 2017

publication date

1 March 2012

1 reference

26 August 2017

number of pages

20

1 reference

inferred from page(s)

published in

Drugs

1 reference

26 August 2017

volume

72

1 reference

26 August 2017

issue

4

1 reference

26 August 2017

page(s)

565-584

1 reference

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Stabilization and regression of coronary plaques treated with pitavastatin proven by angioscopy and intravascular ultrasound--the TOGETHAR trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the Task Force Criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Comparative long-term efficacy and tolerability of pitavastatin 4 mg and atorvastatin 20-40 mg in patients with type 2 diabetes mellitus and combined (mixed) dyslipidaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigatars

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effects of pitavastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Integrated backscatter and intima-media thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: effect of pitavastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Global analysis of RNA expression profile in human vascular cells treated with statins

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC. Human umbilical vein endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Atherosclerosis induced by chronic inhibition of the synthesis of nitric oxide in moderately hypercholesterolaemic rabbits is suppressed by pitavastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Plaque-Stabilizing Effect of Pitavastatin in Watanabe Heritable Hyperlipidemic(WHHL) Rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin inhibits remnant lipoprotein-induced macrophage foam cell formation through ApoB48 receptor-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPARgamma and Pref-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Impact of OATP transporters on pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis pr

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-dens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by rep

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11207180-000000000-00000

A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

12 December 2020

Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.

1 reference

12 December 2020

Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia

1 reference

12 December 2020

Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men.

1 reference

12 December 2020

Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial

1 reference

12 December 2020

Long-term efficacy of pitavastatin versus simvastatin

1 reference

12 December 2020

Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study

1 reference

12 December 2020

Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase

1 reference

12 December 2020

Effect of two intensive statin regimens on progression of coronary disease

1 reference

12 December 2020

Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS

1 reference

12 December 2020

Comparisons of short- and intermediate-term effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function

1 reference

12 December 2020

Rationale and design of a study to evaluate effects of pitavastatin on Japanese patients with chronic heart failure: the pitavastatin heart failure study (PEARL study).

1 reference

12 December 2020

10.2165/11207180-000000000-00000

Identifiers

DOI

1 reference

Dimensions Publication ID

26 August 2017

1030416498

0 references

1 reference